Depression and chronic heart failure in the

1 1 1 1 2, 3 4 1 5, 6 1 1 1,6 1 2 3 4 5 6 Abstract J Geriatr Cardiol 2018; 15: 451?459. doi:10./ 1 Introduction Chronic heart failure (CHF) is a syndrome caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress. [1] [2] [3] 2 Epidemiology CHF is highly prevalent in the elderly population with an incidence of > 4%, one-year mortality of > 20% and a prevalence of > 20% in individuals 3 [4,5] [6] [7] [8–18] [8] [18] [12] [9–11,13,14,16,17,19] [11] [13,15] 3 Pathophysiology The causal relationship between depression and CHF is not clearly understood. Several mechanisms are involved in the physiopathology of CHF and depression which may represent the common ground for their interaction. We have analysed them to hypothesize possible interplays between the two conditions that involve them all (Figure 1). 3.1 Behavioural factors Depressive symptoms, such as increased fatigue, lack of motivation and inability to concentrate compromise patients’ adherence to therapy and healthy lifestyle, with reduced physical activity and increased tobacco and alcohol consumption. This behaviour leads to obesity, atherosclerosis and coronary artery disease, which is the main cause of CHF. [20] [21] [6] [22] 3.2 Neurohormonal activation Stress factors play a key role in CVDs and depression. In both these conditions, the stress response is mediated by the hypothalamic-pituitary-adrenal (HPA) axis, also known to be more active in the elderly, and by the sympathetic branch of the autonomous nervous system (ANS). [23] [24] [25] [26] 3.3 Inflammatory mediators It is well established that the aging process promotes a proinflammatory state in the depression is associated with elevated levels of inflammatory biomarkers and acute-phase proteins, such as interleukine-1 (IL-1), interleukine-6 (IL-6), C Reactive Protein (CRP) and fibrinogen. This pro-inflammatory state is present even when depression is not associated with other medical conditions. [27] [28] [21] [29] [30] [31] 3.4 Hypercoagulability CHF, depression and the aging process independently contribute to a hypercoagulable state. Patients with CHF have higher levels of von Willebrand factor (vWf) and fi-brinogen and increased plasma viscosity and platelet activ-ity. [32] [33] [34] [35] 3.5 Vascular damage In contrast to depressive disorders in younger adults, depression in the elderly, also called late-life depression, is directly associated with ischemic brain lesions. These latter are characterised by white matter hyper-intensities on structural magnetic resonance imagingand frontal and temporal, especially hyppocampal, grey matter changes or atrophy. [36] [37] 3.6 Depression and CHF relationship: an intriguing hypothesis Both depression and CHF are able to negatively affect one-other. These two conditions could possibly interact at several different pathophysiological levels, as previously described. More specifically, starting from a more comprehensive and systemic level, depression and CHF mutually affect themselves through the common pathways related to the induction of a proinflammatory and hypercoagulability state. In this setting, also the neurohormonal dysfunction is involved in both diseases onset and progression. In fact, acting through both hypercortisolism and ANS imbalance, neurohormonal dysfunction not only worsens CHF and other CVDs, but also depression, as hypothesized in the Polyvagal theory. The proinflammatory and hypercoagulability state along with the neurohormonal dysfunction lead to the next level of interaction between depression and CHF, represented by the vascular involvement. This condition is responsible for the onset and worsening of depressive state through ischemic brain lesions but also for the progression of CVDs associated with CHF. Finally, the behavioural component of the interaction between depression and CHF acts when one or both conditions are present contributing either to the rise of the other one or to their mutual worsening (Figure 1), through social issues related to CHF and poor compliance associated to depression. Nevertheless, in order to argue which condition came first, we suggest that would be necessary a type of study that, starting from healthy subjects, follows them in time to detect the development of depression or CHF and consequently treat the condition raised and verify the effect on the development of the other one. Unfortunately, at the present time, this type of study is not available. 4 Clinical findings Depression may be unrecognized in cardiac patients for many reasons, the more important being represented by the similarities between the symptoms of depression and CHF (e.g., low energy, fatigue, sleep disturbance, weight loss or gain, decreased attention and concentration, memory impairment). [38] [39] These symptoms, worsen quality of life (QoL), are independent risk factors for adverse clinical outcomes among CHF patients and are associated with an increased risk of adverse cardiac events thus making their recognition and treatment crucial and time sensitive issues. [30,40] [41] 5 Diagnosis In a meta-analysis of 27 studies, the mean prevalence rate of clinically significant depression among CHF patients was 21.5%, even if this result is influenced by the use of either screening tools or diagnostic interview (33.6% and 19.3%, respectively) and by NYHA class (11% in class I, 42% in class IV). [41] [14] [3] [42] Similarly, the European Society of Cardiology (ESC), in the recently released CHF guidelines, defined as good practice the routine screening for depression in these patients using validated questionnaires. [1] [43] [44] [45] It is important to underline that screening questionnaires facilitate the assessment of depression but cannot stand for a diagnostic interview by mental health professionals and that the diagnosis of major depression is clinical and based on DSM-V criteria. [2] 6 Prognosis In Table 2 [4,16,38,46–51] [4,16,48,49] [52] [38,46] [46] [46,51] [50] [46] [47] [53] 7 Therapy Therapeutic approach in elderly patients with CHF and depression is complex. Of course, CHF therapy should be optimized according to the more recent guidelines. [1] th [4] 7.1 Antidepressants Several studies have been conducted on the use of antidepressants in elderly CHF patients and the results have been conflicting. Fosbol, et al [54] [55] [56] [57,58] [59] b [53] [54,60,61] [60–64] [65,66] b [53] a [67] [68] 7.2 Non-pharmacological interventions Psychotherapy is the application of clinical methods and interpersonal stances derived from established psychological principles with the aim to take care of individual’s mental health problems. This can be reached through several methods, among these the most useful for treating depression is cognitive behavioral therapy (CBT). [20] [69] Several studies show how exercise training is an effective non-pharmacologic therapeutic choice able to reduce depressive symptoms among CHF patients. [69] [39] [70] [1] ECT is considered the “gold standard” in the treatment of geriatric patients with major depression resistant to pharmacotherapy and psychotherapy and who require a rapid response because of the severity of their psychiatric or medical condition. [71] per se [72] [73] 8 Conclusions CHF and depressive disorders have a high prevalence and incidence in the elderly. Depression tends to exacerbate CHF and this latter worsens QoL and leads to the develop-ment of depressive symptoms. Depression is a well-estab-lished independent negative prognostic factor in elderly patients with CHF but is often unrecognized in cardiac pa-tients. Indeed, the negative synergism between CHF and depression in the elderly may be approached only taking into account the multifaceted pathophysiological character-istics underlying both these conditions. Accordingly, a mul-tidisciplinary therapeutical approach represents the prefer-able way to manage this harmful condition, particularly frequent in the elderly. Acknowledgments The authors declare that they have no conflict of interest. References 1 Ponikowski P, Voors AA, Anker SD, et al Eur J Heart Fail 2 American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5 th 3 Rustad JK, Stern TA, Hebert KA, et al Prim Care Companion CNS Disord 4 Testa G, Cacciatore F, Galizia G, et al Eur J Clin Invest 5 Abete P, Testa G, Della-Morte D, et al Heart Fail Rev 6 Cacciatore F, Abete P, Mazzella F, et al Eur J Clin Invest 7 Stranieri G, Carabetta C. Socio-economic cultural transformations and depression in elderly people. Psychiatr Danub 8 Ghosh RK, Ball S, Prasad V, et al Int J Cardiol 9 Tresch DD, Folstein MF, Rabins PV, et al J Am Geriatr Soc 10 Cacciatore F, Testa G, Galizia G, et al. Acta Diabetol 11 Koenig HG. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 12 Abramson J, Berger A, Krumholz HM, et al Arch Intern Med 13 Williams SA, Kasl SV, Heiat A, et al Psychosom Med 14 Yu DS, Lee DT, Woo J, et al J Psychosom Res 15 Gottlieb SS, Khatta M, Friedmann E, et al J Am Coll Cardiol 16 Lesman-Leegte I, Jaarsma T, Sanderman R, et al Eur J Heart Fail 17 Guallar-Castillón P, Magari?os-Losada MM, Montoto-Otero C, et al Rev Esp Cardiol 18 H?gglund L, Boman K, Lundman B, et al Scand J Caring Sci 19 Luijendijk HJ, Tiemeier H, van den Berg JF, et al J Am Geriatr Soc 20 Abete P, Cacciatore F, Ferrara N, et al Am J Clin Nutr 21 Nair N, Farmer C, Gongora E, et al Am J Cardiol 22 Ferrara N, Abete P, Giordano M, et al. Clin Nephrol 23 Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 24 Guder G, Bauersachs J, Frantz S, et al Circulation 25 Porges SW. The polyvagal theory: phylogenetic substrates of a social nervous system. Int J Psychophysiol 26 Otte C, Neylan TC, Pipkin SS, et al Am J Psychiatry 27 Godbout JP, Johnson RW. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Neurol Clin 28 Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 29 Blum A, Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med 30 Koyama A, O'Brien J, Weuve J, et al J Gerontol A Biol Sci Med Sci 31 De Lorenzo F, Saba N, Kakkar VV. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. Drugs 32 Savoy C, Van Lieshout RJ, Steiner M. Is plasminogen activator inhibitor-1 a physiological bottleneck bridging major depressive disorder and cardiovascular disease? Acta Physiol Oxf 33 Rodier M, Prigent-Tessier A, Béjot Y, et al PLoS One 34 Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 35 Aizenstein HJ, Baskys A, Boldrini M, et al BMC Med 36 Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 37 Skotzko CE, Krichten C, Zietowski G, et al J Card Fail 38 Guck TP, Elsasser GN, Kavan MG, et al Congest Heart Fail 39 Jiang W, Kuchibhatla M, Clary GL, et al Am Heart J 40 Kato N, Kinugawa K, Shiga T, et al J Cardiol 41 Rutledge T, Reis VA, Linke SE, et al J Am Coll Cardiol 42 Lichtman JH, Bigger JT Jr, Blumenthal JA, et al Circulation 43 Lahlou-Laforet K, Ledru F, Niarra R, et al J Affect Disord 44 Ski CF, Thompson DR, Hare DL, et al Health Qual Life Outcomes 45 Yesavage JA, Brink TL, Rose TL, et al J Psychiatr Res 46 Sullivan MD, Newton K, Hecht J, et al Am J Geriatr Cardiol 47 Ahmed A, Ali M, Lefante CM, et al Am J Geriatr Psychiatry 48 Johansson P, Dahlstr?m U, Alehagen U. Depressive symptoms and six-year cardiovascular mortality in elderly patients with and without heart failure. Scand Cardiovasc J 49 Macchia A, Monte S, Pellegrini F, et al Eur J Heart Fail 50 Lesman-Leegtel I, Jaarsma T, Coyne JC. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controls. J Card Fail 51 Uchmanowicz I, Gobbens RJ. The relationship between frailty, anxiety and depression, and health-related quality of life in elderly patients with heart failure. Clin Interv Aging 52 Vaccarino V, Kasl SV, Abramson J, et al J Am Coll Cardiol 53 Jünger J, Schellberg D, Müller-Tasch T, et al Eur J Heart Fail 54 Fosb?l EL, Gislason GH, Poulsen HE, et al Circ Heart Fail 55 Veien KT, Videb?k L, Schou M, et al Int J Cardiol 56 Angermann CE, Gelbrich G, St?rk S, et al JAMA 57 Xiong GL, Fiuzat M, Kuchibhatla M, et al Circ Heart Fail 58 O’Connor CM, Jiang W, Kuchibhatla M, et al J Am Coll Cardiol 59 Jiang W, Glassman A, Krishnan R, et al Am Heart J 60 Hippisley-Cox J, Pringle M, Hammersley V, et al BMJ 61 Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 62 Hamer M, Batty GD, Seldenrijk A, et al Eur Heart J 63 Monster TB, Johnsen SP, Olsen ML, et al Am J Med 64 Brouwers C, Christensen SB, Damen NL, et al Int J Cardiol 65 Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 66 Schlienger R, Fischer LM, Jick H, et al Drug Saf 67 Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 68 Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: a narrative review. ARYA Atheroscler 69 Herring MP, Puetz TW, O'Connor PJ, et al Arch Intern Med 70 Tu RH, Zeng ZY, Zhong GQ, et al Eur J Heart Fail 71 McDonald WM. Neuromodulation treatments for geriatric mood and cognitive disorders. Am J Geriatr Psychiatry 72 Kerner N, Prudic J. Current electroconvulsive therapy practice and research in the geriatric population. Neuropsychiatry London 73 Zielinski RJ, Roose SP, Devanand DP, et al Am J Psychiatry

文章来源：《中国药理学与毒理学杂志》 网址: http://www.zgylxydlxzz.cn/qikandaodu/2020/1010/351.html